Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 22, 2024

BUY
$190.52 - $236.72 $183,280 - $227,724
962 New
962 $223,000
Q4 2023

Feb 06, 2024

BUY
$222.59 - $267.94 $1.36 Million - $1.63 Million
6,088 New
6,088 $1.58 Million
Q2 2021

Jan 28, 2022

SELL
$259.0 - $414.71 $1.54 Million - $2.47 Million
-5,950 Closed
0 $0
Q1 2021

Jan 27, 2022

BUY
$242.95 - $284.63 $1.45 Million - $1.69 Million
5,950 New
5,950 $1.67 Million
Q4 2020

Feb 11, 2021

SELL
$236.26 - $355.63 $1.65 Million - $2.49 Million
-7,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $1.55 Million - $1.79 Million
5,849 Added 508.17%
7,000 $1.99 Million
Q2 2020

Aug 11, 2020

BUY
$258.66 - $342.55 $76,046 - $100,709
294 Added 34.31%
1,151 $308,000
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $15,593 - $19,780
-58 Reduced 6.34%
857 $271,000
Q4 2019

Feb 13, 2020

BUY
$220.06 - $304.07 $201,354 - $278,224
915 New
915 $272,000
Q3 2019

Nov 08, 2019

SELL
$217.44 - $243.88 $195,043 - $218,760
-897 Closed
0 $0
Q2 2019

Aug 16, 2019

SELL
$219.29 - $241.72 $11,403 - $12,569
-52 Reduced 5.48%
897 $210,000
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $3,467 - $5,423
16 Added 1.71%
949 $224,000
Q4 2018

Feb 08, 2019

SELL
$278.5 - $352.75 $1.4 Million - $1.78 Million
-5,039 Reduced 84.38%
933 $281,000
Q3 2018

Nov 15, 2018

SELL
$293.51 - $383.83 $32,286 - $42,221
-110 Reduced 1.81%
5,972 $2.11 Million
Q2 2018

Aug 10, 2018

SELL
$257.52 - $306.91 $4.7 Million - $5.6 Million
-18,248 Reduced 75.0%
6,082 $1.77 Million
Q1 2018

May 03, 2018

SELL
$260.13 - $367.91 $1.47 Million - $2.08 Million
-5,663 Reduced 18.88%
24,330 $6.66 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $9.23 Million - $10.3 Million
29,993
29,993 $9.56 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.